Provexis plc (AIM:PXS)
London · Delayed Price · Currency is GBP · Price in GBX 0.6000
-0.0025 (-0.41%)
Oct 31, 2025, 1:54 PM GMT+1
Provexis Revenue
In the fiscal year ending March 31, 2025, Provexis had annual revenue of 1.29M GBP with 61.13% growth. Provexis had revenue of 785.35K in the half year ending September 30, 2024, with 337.84% growth.
Revenue
1.29M
Revenue Growth
+61.13%
P/S Ratio
10.47
Revenue / Employee
646.12K
Employees
2
Market Cap
13.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.29M | 490.28K | 61.13% |
| Mar 31, 2024 | 801.96K | 412.05K | 105.68% |
| Mar 31, 2023 | 389.92K | -36.25K | -8.51% |
| Mar 31, 2022 | 426.17K | -79.16K | -15.67% |
| Mar 31, 2021 | 505.33K | 157.39K | 45.24% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |